Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPA | P38571 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194764 | 1.00 | LIPA (0.47) | LIPACDC25BEPHX1HSD11B1ESR1 | |
| SCHEMBL10888768 | 1.00 | LIPA (0.47) | LIPACDC25BEPHX1HSD11B1ESR1 | |
| SCHEMBL9815832 | 0.86 | ESR1 (0.35) | LIPAESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL14217165 | 0.85 | LIPA (0.40) | LIPACDC25BEPHX1HSD11B1NR1H2 | |
| SCHEMBL18721001 | 0.85 | LIPA (0.40) | LIPACDC25BEPHX1HSD11B1NR1H2 | |
| SCHEMBL18720992 | 0.85 | LIPA (0.40) | LIPACDC25BEPHX1HSD11B1NR1H2 | |
| SCHEMBL13766715 | 0.85 | LIPA (0.40) | LIPACDC25BEPHX1HSD11B1NR1H2 | |
| SCHEMBL9815771 | 0.84 | ESR1 (0.34) | LIPAESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL1958414 | 0.82 | CES2 (0.38) | LIPAESR1ESR2CYP3A4CYP2C9 | |
| SCHEMBL1958415 | 0.82 | CES2 (0.38) | LIPAESR1ESR2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072637-A1 | OXYGENATED HETEROCYCLIC LSD-1 INHIBITORS AND RELATED METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170151138-A1 | METHOD FOR REDUCING PERSPIRATION AND/OR BODY ODOR USING SPECIFIC ALCOHOLS | HENKEL AG & CO. KGAA (DE) | 2017-06-01 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-0077550-B1 | 1.4-NAPHTHOQUINONES, METHODS FOR THEIR PREPARATION AND VETERINARY FORMULATIONS THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1985-07-10 | — | — | EP | disclosed |
| US-4485116-A | NAPHTHOQUINONE COMPOUNDS | BURROUGHS WELLCOME CO. | 1984-11-27 | — | — | US | disclosed |
| EP-0077550-A2 | 1.4-Naphthoquinones, methods for their preparation and veterinary formulations thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | LIPA 247/4885CDC25B 1684/4885EPHX1 1557/4885 |
| US-20170151138-A1 | METHOD FOR REDUCING PERSPIRATION AND/OR BODY ODOR USING SPECIFIC ALCOHOLS | ADH1A, ADH1C, CUTA | LIPA 450/4885CDC25B 811/4885EPHX1 547/4885 |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | LIPA 4289/4885CDC25B 1010/4885EPHX1 2023/4885 |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | LIPA 4289/4885CDC25B 1010/4885EPHX1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.